KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Receivables: 2012-2024

Historic Change in Receivables for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $614,000.

  • Xenon Pharmaceuticals' Change in Receivables fell 440.96% to -$283,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$116,000, marking a year-over-year decrease of 132.13%. This contributed to the annual value of $614,000 for FY2024, which is 572.31% up from last year.
  • As of FY2024, Xenon Pharmaceuticals' Change in Receivables stood at $614,000, which was up 572.31% from -$130,000 recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Change in Receivables peaked at $1.0 million during FY2020, and registered a low of -$1.8 million during FY2022.
  • In the last 3 years, Xenon Pharmaceuticals' Change in Receivables had a median value of -$130,000 in 2023 and averaged -$424,333.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Change in Receivables crashed by 482.79% in 2022, and later surged by 572.31% in 2024.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Change in Receivables stood at $1.0 million in 2020, then crashed by 55.52% to $459,000 in 2021, then crashed by 482.79% to -$1.8 million in 2022, then spiked by 92.60% to -$130,000 in 2023, then spiked by 572.31% to $614,000 in 2024.